[68] Töyry JP, Niskanen LK, Mäntysaari MJ, Länsimies EA, Uusitupa MIJ. Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM, Ten-year follow up from the diagnosis. Diabetes 1996; 45: 308-15.
[69] Töyry JP, Niskanen LK, Lansimies EA, Partanen KPL, Uusitupa MIJ. Autonomic neuropathy predicts the development of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1996; 27: 1316-8.
[70] Mustonen J, Uusitupa M, Mäntysaari M, Länsimies E, Pyörälä K, Laakso M. Changes in autonomic nervous function during the 4-year follow-up in middle-aged diabetic and nondiabetic subjects initially free of coronary heart disease. J Intern Med 1997; 241: 227-35.
[71] Quadri R, Ponzani P, Zanone M, Maule S, Grotta A La, Papotti G, Valentini M, Matteoda C, Chiandussi L, Fonzo D. Changes in autonomic nervous function over a 5-year period in non-insulin-dependent diabetic patients. Diabet Med 1993; 10: 916-9.
[72] Ziegler D, Mayer P, Mühlen H, Gries FA. The natural history of somatosensory and autonomic nerve dysfunction in relation to glycaemic control during the first 5 years after diagnosis of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 822-9.
[73] Solders G, Thalme B, Aguirre-Aquino M, Brandt L, Berg U, Persson A. Nerve conduction and autonomic nerve function in diabetic children. Acta Paediatr 1997; 86: 361-6.
[74] Sampson MJ, Wilson S, Karagiannis P, Edmonds M, Watkins PJ. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. QJ Med 1990; 75: 635-46.
[75] Sundkvist G, Lilja B. Autonomic neuropathy in diabetes mellitus: a follow-up study. Diabetes Care 1985; 8: 129-33.
[76] Donaghue KC, Fung ATW, Fairchild JM, Howard NJ, Silink M. Prospective assessment of autonomic and peripheral nerve function in adolescents with diabetes. Diabet Med 1996; 13: 65-71.
[77] Levitt NS, Stansberry KB, Wynchank S, Vinik AI. The natural progression of autonomic neuropathy aund autonomic function tests in a cohort of people with IDDM. Diabetes Care 1996; 19: 751-4.
[78] Sundkvist G, Lilja B. Autonomic neuropathy predicts deterioration in glomerular filtration rate in patients with IDDM. Diabetes Care 1993; 16: 773-9.
[79] Ziegler D, Piolot R, Pour Mirza A, Karallus M, Feng B, Schommartz B, Schadewaldt P. 13C-octanoic acid breath test to assess diabetic gastroparesis: patterns of gastric emptying in newly diagnosed and long-term type 1 and type 2 diabetic patients. Clin Auton Res 1997; 7: 246.
[80] Enck P, Rathmann W, Spiekermann M, Czerner D, Tschöpe D, Ziegler D, Strohmeyer G, Cries FA. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z Gastroenterol 1994; 32: 637-41.
[81] Schvarcz E, Palmer M, Ingberg CM, Aman J, Berne C. Increased prevalence of upper gastrointestinal symptoms in long-term type 1 diabetes mellitus. Diabet Med 1996; 13: 478-81.
[82] Ko GTC, Chan W-B, Chan JCN, Tsang LWW, Cockram CS. Gastrointestinal symptoms in Chinese patients with type 2 diabetes mellitus. Diabet Med 1999; 16: 670-4.
[83] Santis A De, Attili AF, Corradini SG, Scafato E, Cantagalli A, Luca C De, Pinto G, List D, Capocaccia L. Gallstones and diabetes: a case-control study in a free-living population sample. Hepatology 1997; 25: 787-90.
[84] Shaw JE, Parker R, Hollis S, Gokal R, Boulton AJM. Gustatory sweating in diabetes mellitus. Diabet Med 1996; 13: 1033-7.
[85] NIH consensus development panel on impotence. Impotence. JAMA 1993; 270: 83-90.
[86] Wagner G, Saenz de Tejada I. Update on male erectile dysfunction. BMJ 1998; 316: 678-82.
[87] Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts male ageing study. J Urol 1994; 151: 54-61.
[88] Fedele D, Coscelli C, Santeusanio F, Bortolotti A, Chatenoud L, Colli E, Landoni M, Parazzini F. Erectile dysfunction in diabetic subjects in Italy. Diabetes Care 1998; 21: 1973-7.
[89] Kolodny RC, Kahn CB, Goldstein HH, Barnett DM. Sexual dysfunction in diabetic men. Diabetes 1974; 23: 306-9.
[90] Klein R, Klein PEK. Lee KE, Moss SE, Cruickshanks KJ. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 1996; 19: 135-41.
[91] McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia 1980; 18: 279-83.
[92] Cavan DA, Barnett AH, Leatherdale BA. Diabetic impotence: risk factors in a clinic population. Diabetes Res 1987; 5: 145-8.
[93] Hackett GI. Impotence–the most neglected complication of diabetes. Diabetes Care 1995; 28: 75-83.
[94] Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP. McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000; 163: 460-3.
[95] Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996; 39: 1483-8.
[96] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
[97] Dyck PJ, Davies JL, Wilson DM, Service JF, Melton III. LJ, O'Brien PC. Risk factors for severity of diabetic polyneuropathy. Diabetes Care 1999; 22: 1479-86.
[98] Wiles PC, Pearce SM, Rice PJ, Mitchell JM. Vibration perception threshold: influence of age, height, sex, and smoking, and calculation of accurate centile values. Diabet Med 1991; 8: 157-61.
[99] Bloom S, Till S, Sonksen P, Smith S. Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non-diabetic subjects. Br Med J (Clin Res Ed) 1984; 288: 1793-5.
[100] Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996; 19: 1243-8.
[101] Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, Boulton AJ. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352: 1978-81.
[102] UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 3BMJ 1998; 317: 703-13.
[103] Ido Y, Vindigni A, Chang K, Stramm L, Chance R, Heath WF, DiMarchi RD, Di Cera E, Williamson JR. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997; 277: 563-6.
[104] Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW, Cai J, Sharrett AR. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care 1998; 21: 2116-22.
[105] Liao D, Cai J, Brancati FL, Folsom A, Barnes RW, Tyroler HA, Heiss G. Association of vagal tone with serum insulin, glucose, and diabetes mellitus–the ARIC Study. Diabetes Res Clin Pract 1995; 30: 211-21.
[106] Dekker JM, Feskens EJM, Schouten EG, Klootwijk P, Pool J, Kromhout D. QTc duration is associated with levels of insulin and glucose tolerance. Zutphen Elderly Study. Diabetes 1996; 45: 376-80.
[107] 10Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis, and treatment. Diabetes Metab Rev 1994; 10: 339-83.
[108] Gerritsen